Compare Boston Scientific Corporation (BSX) vs VanEck Gold Miners ETF (GDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs VanEck Gold Miners ETF — how do they compare? Boston Scientific Corporation trades at $51.58 (market cap $74.19B), while VanEck Gold Miners ETF trades at $90.89. The key difference: VanEck Gold Miners ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | GDX | |
|---|---|---|
Market Cap | $74.19B | — |
Sector | Health | — |
52-Week High | $108.14 | $115.84 |
52-Week Low | $42.63 | $56.60 |
Enterprise Value | $86.27B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $51.66, up 2.38% today, showing strong momentum with three consecutive quarterly earnings beats. The stock maintains bullish technical signals with moving averages supporting upward movement, though oscillators indicate potential overbought conditions. Fundamentally, BSX demonstrates robust growth with 2025 revenue reaching $20.07B and net income margin expanding to 14.43%, supported by strong cash flow generation of $1.54B in 2025.
The outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target offering 30% upside potential. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with recent guidance cuts. Insider buying by the CEO and director signals management confidence in the company's long-term prospects despite near-term challenges.
GDX (VanEck Gold Miners ETF) trades at $90.96, up 0.52% with a bullish technical signal from moving averages but overbought RSI readings. The ETF benefits from gold's seven-week rally to near $4,300/oz, though mining stocks have lagged the metal's gains. Recent institutional activity shows mixed sentiment with City Holding reducing its position by 85.8% while Axiom Investment added a $934,000 stake in Q1 2026.
Gold miners offer leveraged exposure to rising gold prices with attractive valuations, but face volatility risks. The sector's free cash flow yields are at record highs, supporting potential upside if gold sustains momentum. Key risks include gold price sensitivity, mining operational challenges, and competition from physical gold ETFs with lower expense ratios.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →
